Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457076 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL14829261 | 0.85 | MEN1 (0.67) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL3455269 | 0.84 | MEN1 (0.64) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL23149159 | 0.83 | ATF4 (0.71) | KMT2AMEN1HPGDLMNANPC1 | |
| SCHEMBL1758671 | 0.81 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL4400605 | 0.81 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL4223078 | 0.80 | EPHX2 (0.71) | ALDH1A1KMT2AMEN1HPGDKDM4E | |
| SCHEMBL1420777 | 0.78 | FAAH (0.61) | ALDH1A1KMT2AMEN1HPGDTSHR | |
| SCHEMBL20998386 | 0.78 | ATF4 (0.64) | KMT2AMEN1HPGDHTTNPC1 | |
| SCHEMBL19798449 | 0.77 | KMT2A (0.72) | ALDH1A1KMT2AMEN1HTTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269977-B1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| CN-101300005-B | N-2 adamantyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-05-01 | — | — | CN | disclosed |
| US-8344181-B2 | Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-01 | — | — | US | disclosed |
| EP-1846363-B1 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-04-25 | — | — | EP | disclosed |
| CN-101300005-A | N-2 adamantyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-05 | — | — | CN | disclosed |
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | ALDH1A1 410/4885KMT2A 2781/4885MEN1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.